Electra Therapeutics Expands Ipsoprubart Program With Phase 1 Trial in T Cell Malignancies

New updates have been reported about Electra Therapeutics.

Electra Therapeutics has dosed the first patient in a Phase 1 trial evaluating its lead asset ipsoprubart (ELA026) as monotherapy for relapsed or refractory T cell malignancies, marking a strategic expansion of the program beyond its ongoing pivotal trial in secondary hemophagocytic lymphohistiocytosis (sHLH). The first-in-class monoclonal antibody targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological T cells and myeloid cells, with the company positioning it as a potential new option in a rare, aggressive lymphoma and leukemia segment where more than 13,000 U.S. patients annually face limited durable treatments.

The open-label Phase 1 trial will enroll adults for up to six 4-week treatment cycles, with Part 1 testing up to 24 patients to determine as many as two safe dosing regimens and Part 2 expanding into additional cohorts to further assess these regimens, focusing primarily on safety and secondarily on response rate, duration of response, and disease control. Electra’s decision follows earlier Phase 1b sHLH data in lymphoma-associated disease, where eight patients, including six with T cell malignancies, showed a 100% objective tumor response and an 88% complete response rate, including a durable complete response on ipsoprubart monotherapy in a patient refractory to more than five prior lines of therapy, which has generated strong investigator interest and underpins the company’s broader SIRP-targeting portfolio that also includes its second candidate, ELA822, for immunology and inflammation indications.